Accuray Incorporated · NASDAQ:ARAY
Accuray — Q1 FY2024 Earnings Presentation
14 slides from Accuray's earnings presentation, Nov 7, 2023
Slide 1: Q1'FY24 Earnings Call Supplemental Presentation
Q1’FY24 Earnings Call Supplemental Presentation November 7, 2023
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. 2 Proprietary and Confidential Property of Accuray Safe Harbor Statement Statements in this presentation (including the oral commentary that accompanies it) that are
Slide 3: Delivering on Our Strategy
ACCURAY . C) Delivering on Our Strategy <q
Slide 4: Closing the Gaps to Cancer Care
Closing the Gaps to Cancer Care Advance Care by providing solutions that address the biggest pain points in RT Drive Patient Access to radiotherapy treatments in developed and high potential underserved markets Delight Customers by ensuring high operational performance so no patient is rescheduled H
Slide 5: Our Strategic Growth Plan: Key Pillars
Our Strategic Growth Plan: Key Pillars Guided by Our Vision: To expand the curative power of radiation therapy to improve as many lives as possible Outpace market growth with innovations Operational excellence and efficiency Expand service revenue with installed base growth and focus on uptime Profi
Slide 6: Patient-Focused Innovations
Patient-Focused Innovations Advancing care through partnerships Proprietary and Confidential Property of Accuray FDA 510(k) clearance in the U.S. and CE mark in the EU market for VitalHold™1 breast cancer treatment package for the Radixact® System NMPA regulatory approval for Tomo® C, the Joint Vent
Slide 7: Innovation Highlights from ASTRO
Innovation Highlights from ASTRO Exceptional quality diagnostic-like CT imaging Driving Radixact new system demand ClearRT™ VitalHold™1 Surface Guided RT for breast cancer therapy Available in US, EU; Japan/Sonin pending Alliance A+ Value-added Service solutions Accuray Financial Services Online Ada
Slide 8: PACE B Prostate Study Shows SBRT Is as Effective as Conventional Radiation Therapy
~ 1 in 8 men in the U.S. will be diagnosed with prostate cancer2 Phase 3 trial testing 5-fraction SBRT vs 20- or 39-fraction conventional radiation therapy1 N=874 patients, 38 centers, 3 countries1 Conclusion PACE A + PACE B: “SBRT should be considered a new standard of care in low and intermediate
Slide 9: Q1'FY24 Financials
Q1’FY24 Financials Strong financial performance Gross orders $63.7M (9%) Revenues $103.9M 8% Product $53.3M 17%3 Service $50.5M (1%)3 Op. Expenses $37.3M 1% R&D $14.0M (1%) SG&A $23.3M 3% Adj. EBITDA 1 $6.5M 243% KEY FINANCIAL METRICS $M Q1 Y/Y Highlights Robust orders with book-to-bill ratio of 1.2
Slide 10: Maintaining FY24 Guidance
Maintaining FY24 Guidance Communicated August 9, 2023 Takes into account expectations regarding uncertainty and impact from macro environmental climate, FX and inflation Revenue Adjusted EBITDA1 $447.6M $23.9M FY24 Guidance Range FY23 Actual $ in millions % = YoY Growth $460M - $470M +3% - 5% $27M -
Slide 11: Accuray at the Jefferies Conference
Accuray at the Jefferies Conference Proprietary and Confidential Property of Accuray Accuray will participate in the 14th Annual Jefferies London Healthcare Conference CEO Suzanne Winter and CFO Ali Pervaiz will share prepared remarks and take part in a moderated Q&A Wednesday, November 15th, 2023,
Slide 12: Thank you
ACCURAY Thank you
Slide 13: GAAP to Adjusted EBITDA Q1 FY'24 and Q1 FY'23 Actual
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization Three Months Ended September 30, 2023 Three Months Ended September 30, 2022 $ $ $ $ (2,969) 1,251 2,392 2,628 1,932 6,504 (5,449) 1,176 2,916 2,256 341 1,
Slide 14: GAAP to Adjusted EBITDA FY'24 Forward Looking Guidance
$K GAAP net income (loss) Stock-based compensation Interest expense, net Provision for income taxes Adjusted EBITDA Depreciation and amortization To From $ $ $ $ (1,000) 4,500 10,500 10,000 2,000 27,000 2,000 4,500 10,500 10,000 2,000 30,000 ERP and ERP related expenditures 1,000 1,000 GAAP to Adjus